Great Basin Sci (GBSN) 0.20 $GBSN
Great Basin Announces Reverse Stock Split of Common Stock
Business Wire - Fri Mar 25, 12:20PM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today a 1-for-35 reverse split of its common stock. The Company expects that it will be effective at 5:00 pm EDT on March 30, 2016 and that the Company's common stock will open for trading on the Nasdaq Capital Market on Thursday, March 31, 2016 on a post-split basis. At the effective time of the reverse stock split, every 35 shares of the Company's issued and outstanding common stock, par value $0.0001, will be consolidated into 1 newly issued and outstanding share of common stock, par value of $0.0001.
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
Great Basin Scientific Announces Results of Special Meeting
Business Wire - Thu Mar 24, 11:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today that it held a special meeting of stockholders at which the stockholders approved a reverse stock split of the Company's common stock, and the issuance of shares of common stock above the NASDAQ limit of 20% upon conversion of the Company's senior secured convertible notes and the elimination of the exercise floor price in the Company's series D warrants pursuant to the rules of The Nasdaq Capital Market. A third-party proxy management firm tabulated the proxy votes for the special meeting. A detailed description of each proposal and the results of the votes are as follows:
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
These 5 Under-$10 Stocks Are Set to Soar Higher
at The Street - Thu Mar 24, 9:50AM CDT
These under-$10 stocks look poised to break out and trade higher from current levels.
AVGR: 8.83 (-0.14), UEPS: 9.01 (+0.09), CDRB: 3.28 (+0.65), GBSN: 0.20 (-0.08), MRNS: 5.22 (+0.30), PTX: 1.15 (-0.17), IPWR: 4.12 (-0.15), CHNR: 2.12 (-0.46), IMMY: 4.02 (-0.10)
GREAT BASIN SCIENTIFIC, INC. (NASDAQ:GBSN) Analyst Suggested Revenue and Price Target
ACCESSWIRE - Wed Mar 23, 11:14AM CDT
SALT LAKE CITY, UT / ACCESSWIRE / March 23, 2016 / Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, announced today that the U.S. Food & Drug Administration (FDA) has granted 510(k) clearance for its Shiga Toxin Direct Test. Which brings us to the question what is the potential revenue forecast and price targets analyst are suggesting. This new coverage initiated today is the topic of the full report below.
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
Stocks to Buy Today Wednesday March 23, 2016
ACCESSWIRE - Wed Mar 23, 11:10AM CDT
MIAMI, FL / ACCESSWIRE / March 23, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. GBSN, NETE, COOL, and NXTD have been added to our watch list today. Continue reading to find out why. - To daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
NETE: 0.41 (+0.02), GBSN: 0.20 (-0.08), COOL: 0.89 (+0.01), GBSNU: 16.22 (-0.28), NXTD: 0.50 (+0.01)
Great Basin Receives FDA 510(k) Clearance for Shiga Toxin Direct Test
Business Wire - Wed Mar 23, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today that the U.S. Food & Drug Administration (FDA) has granted 510(k) clearance for its Shiga Toxin Direct Test. The Company received notification of clearance from the FDA on March 22, 2016. The Company continues to execute against its menu expansion objectives, now providing the only FDA-cleared stand-alone molecular test to detect Shiga toxin-producing E. coli (STEC) and the serotype O157 directly from a patient specimen. The Shiga Toxin Direct Test can be run on the Great Basin Analyzer, which also performs Great Basin's commercially available low-plex tests for Clostridium difficile (C. diff) and Group B Streptococcus (GBS), as well as the Company's multi-plex Staph ID/R Blood Culture Panel, which is pending 510(k) clearance from the FDA.
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
Great Basin's Ryan Ashton to Present at ROTH Conference
Business Wire - Thu Mar 03, 3:05PM CST
Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, announced today that co-founder and Chief Executive Officer, Ryan Ashton, will speak at the 28th Annual ROTH Conference on March 14 at 5PM PDT. Mr. Ashton and Jeff Rona, Great Basin's Chief Financial Officer, will also be available for one-on-one and group meetings with conference participants on March 14 and 15. To schedule a meeting, please contact oneononerequests@roth.com. More information can be found on the ROTH Capital Partners website at www.roth.com
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
Great Basin prices equity offering; shares down 19%
Seeking Alpha - at Seeking Alpha - Fri Feb 19, 8:58AM CST
GBSN: 0.20 (-0.08)
Great Basin Scientific Prices $6.3 Million Public Offering of Units
Business Wire - Fri Feb 19, 8:29AM CST
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, today announced it has priced a public offering of 39.2 million units at a public offering price of $0.16 per unit. The Company expects that the gross proceeds of the offering of the units will be approximately $6.3 million. Each unit will consist of one share of common stock and 1.5 Series E warrants. Each whole Series E warrant will entitle the holder to acquire one share of common stock, subject to adjustment, at an exercise price of $0.25 per share for a period of five years following the date they first become exercisable. The Series E warrants will not be exercisable until at least one year from the date of issuance and exercise of the Series E warrants is subject to certain stockholder approval requirements.
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
CORRECTING and REPLACING Great Basin Announces 201 Customers to End January 2016
Business Wire - Wed Feb 03, 12:30PM CST
Please replace the release due to changes in the fourth paragraph. The original release stated that Great Basin's Staph ID/R Blood Culture panel is a direct from whole blood multiplex panel. The panel is not direct from whole blood.
GBSN: 0.20 (-0.08)
Great Basin Announces 201 Customers to End January 2016
Business Wire - Wed Feb 03, 7:00AM CST
Great Basin Scientific, Inc. (NASDAQ:GBSN) announced today that its customer base grew to 201 sites by the end of January, up from 186 at the end of December 2015, continuing the Company's steady overall growth for its sample-to-result molecular diagnostics platform.
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
Identifying Opportunity in Market Momentum -- New Research on Great Basin Scientific, Aegean Marine Petroleum Network, Crawford & Co, and Kelso Technologies
ACCESSWIRE - Fri Jan 29, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / January 29, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Great Basin Scientific Inc. (NASDAQ: GBSN), Aegean Marine Petroleum Network Inc. (NYSE: ANW), Crawford & Co. (NYSE: CRD.
and Kelso Technologies Inc. (NYSEMKT: KIQ). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
ANW: 7.50 (+0.27), GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28), CRD.B: 5.78 (-0.04), KIQ: 0.85 (-0.01)
Great Basin's Sandra Nielsen Recognized with Utah Business Annual Sales & Marketer of the Year (SAMY) Award
Business Wire - Tue Jan 26, 7:00AM CST
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, today announced that Utah Business magazine has honored Sandra Nielsen, Vice President, Sales, Marketing & HR with a 2016 SAMY award. The Utah Business SAMY awards aim to recognize Utah's top sales and marketing professionals who have had a measurable impact on their company's bottom line. Ms. Nielsen will accept her award later today during the SAMY Honoree Award Luncheon held at the Grand America Hotel in Salt Lake City.
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
Great Basin Scientific Inc. (NASDAQ: GBSN) Toxic Financing Eliminated from Great Basin's Balance Sheet
ACCESSWIRE - Tue Jan 26, 6:50AM CST
WEST VALLEY, UT / ACCESSWIRE / January 26, 2016 / Great Basin Scientific Inc. (NASDAQ: GBSN) a molecular diagnostics company, announced recently that it has converted all outstanding Series C Warrants into shares of its common stock and therefore now has 75.5 million shares of common stock issued and outstanding, and has no remaining unconverted Series C Warrants. On January 21, 2016, Great Basin converted the remaining 1,221,587 Series C Warrants. It settled 1,416 warrants with cash and settled the remainder by issuing 13.7 million shares of Great Basin common stock. The Company did not issue any of the Pre-funded Rights to acquire its common stock. This toxic financing has been eliminated from GBSN's balance sheet; a step for the better in the eyes of shareholders.
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
Great Basin Announces Conversion of Remaining Series C Warrants
Business Wire - Thu Jan 21, 7:00PM CST
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today that as of 5 p.m. the Company has converted all outstanding Series C Warrants into shares of its common stock and therefore now has 75.5 million shares of common stock issued and outstanding, and has no remaining unconverted Series C Warrants.
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
Great Basin Announces Pricing of Final Series C Warrant Conversions
Business Wire - Wed Jan 20, 9:16PM CST
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, today announced the Company will have sufficient authorized, unreserved and unissued shares of common stock to convert all remaining Series C warrants to shares of its common stock. Therefore, effective 5 p.m. New York City time on Thursday, January 21, 2016, each unexercised Series C warrant will automatically convert into 11.18 shares of Great Basin common stock or to a pre-funded right to acquire 11.18 of shares of Great Basin common stock or a combination thereof. Upon conversion of the remaining Series C Warrants, Great Basin will have approximately 75.5 million shares of common stock outstanding (including pre-funded rights which are convertible into shares of common stock).
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
4 Small Cap NASDAQ/NYSE Stocks That Are Trading with Heavy Volume Today
ACCESSWIRE - Tue Jan 19, 11:52AM CST
NEW YORK, NY / ACCESSWIRE / January 19, 2016 / The Stock Expert is issuing a report on four stocks to watch. CMRX, AEZS, TMST and GBSN have been attracting the attention of major investors today. Continue reading to find out why.
GBSN: 0.20 (-0.08), TMST: 9.04 (+0.73), CMRX: 4.86 (+0.10), AEZS: 3.40 (-0.03)
Great Basin Announces Update of Series C Warrant Conversions
Business Wire - Tue Jan 19, 7:00AM CST
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, today announced that it has approximately 60MM authorized, unreserved and unissued shares remaining and approximately 4.3MM remaining Series C warrants (including Series C Warrants acquirable upon exercise of outstanding options), which, if converted at Friday's closing bid price of $0.15 would require the Company to issue approximately 64MM shares of common stock and would result in an "Authorized Share Failure" as defined under the Series C warrant agreement.
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
Great Basin Announces 186 Customers to End 2015
Business Wire - Tue Jan 05, 7:00AM CST
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, today announced it added 46 new customers in the fourth quarter of 2015. As of December 31st, the company had secured 186 U.S. customers, compared to 84 customers reported at the end of December 2014, representing an increase of 121 percent year over year. Further, Great Basin's Group B Streptococcus (GBS) test--which was commercially launched on June 1, 2015--has now been adopted by or is scheduled to be evaluated by 80 sites, which represents 43 percent of the Company's customer base.
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
4 Small Cap Stocks For Your Portfolio In 2016
ACCESSWIRE - Thu Dec 31, 8:45AM CST
NEW YORK, NY / ACCESSWIRE / December 31, 2015 / UltimateStockAlerts.com is a NASDAQ & NYSE Only Stock Alert Service focused on day trading, swing trading and long-term investing. Our newsletter subscribers have witnessed upside gains in excess of 600% with realized gains of 292% in 2015 from 31 alerts. Receive free trade alerts via email or text message (SMS) on your phone by texting message ULTIMATE to number 555-888. Today we are taking a look at four companies which we believe could provide investors with significant upside.
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
Great Basin Announces Reverse Stock Split of Common Stock
Business Wire - Fri Mar 25, 12:20PM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today a 1-for-35 reverse split of its common stock. The Company expects that it will be effective at 5:00 pm EDT on March 30, 2016 and that the Company's common stock will open for trading on the Nasdaq Capital Market on Thursday, March 31, 2016 on a post-split basis. At the effective time of the reverse stock split, every 35 shares of the Company's issued and outstanding common stock, par value $0.0001, will be consolidated into 1 newly issued and outstanding share of common stock, par value of $0.0001.
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
Great Basin Scientific Announces Results of Special Meeting
Business Wire - Thu Mar 24, 11:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today that it held a special meeting of stockholders at which the stockholders approved a reverse stock split of the Company's common stock, and the issuance of shares of common stock above the NASDAQ limit of 20% upon conversion of the Company's senior secured convertible notes and the elimination of the exercise floor price in the Company's series D warrants pursuant to the rules of The Nasdaq Capital Market. A third-party proxy management firm tabulated the proxy votes for the special meeting. A detailed description of each proposal and the results of the votes are as follows:
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
These 5 Under-$10 Stocks Are Set to Soar Higher
at The Street - Thu Mar 24, 9:50AM CDT
These under-$10 stocks look poised to break out and trade higher from current levels.
AVGR: 8.83 (-0.14), UEPS: 9.01 (+0.09), CDRB: 3.28 (+0.65), GBSN: 0.20 (-0.08), MRNS: 5.22 (+0.30), PTX: 1.15 (-0.17), IPWR: 4.12 (-0.15), CHNR: 2.12 (-0.46), IMMY: 4.02 (-0.10)
GREAT BASIN SCIENTIFIC, INC. (NASDAQ:GBSN) Analyst Suggested Revenue and Price Target
ACCESSWIRE - Wed Mar 23, 11:14AM CDT
SALT LAKE CITY, UT / ACCESSWIRE / March 23, 2016 / Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, announced today that the U.S. Food & Drug Administration (FDA) has granted 510(k) clearance for its Shiga Toxin Direct Test. Which brings us to the question what is the potential revenue forecast and price targets analyst are suggesting. This new coverage initiated today is the topic of the full report below.
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
Stocks to Buy Today Wednesday March 23, 2016
ACCESSWIRE - Wed Mar 23, 11:10AM CDT
MIAMI, FL / ACCESSWIRE / March 23, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. GBSN, NETE, COOL, and NXTD have been added to our watch list today. Continue reading to find out why. - To daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
NETE: 0.41 (+0.02), GBSN: 0.20 (-0.08), COOL: 0.89 (+0.01), GBSNU: 16.22 (-0.28), NXTD: 0.50 (+0.01)
Great Basin Receives FDA 510(k) Clearance for Shiga Toxin Direct Test
Business Wire - Wed Mar 23, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today that the U.S. Food & Drug Administration (FDA) has granted 510(k) clearance for its Shiga Toxin Direct Test. The Company received notification of clearance from the FDA on March 22, 2016. The Company continues to execute against its menu expansion objectives, now providing the only FDA-cleared stand-alone molecular test to detect Shiga toxin-producing E. coli (STEC) and the serotype O157 directly from a patient specimen. The Shiga Toxin Direct Test can be run on the Great Basin Analyzer, which also performs Great Basin's commercially available low-plex tests for Clostridium difficile (C. diff) and Group B Streptococcus (GBS), as well as the Company's multi-plex Staph ID/R Blood Culture Panel, which is pending 510(k) clearance from the FDA.
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
Great Basin's Ryan Ashton to Present at ROTH Conference
Business Wire - Thu Mar 03, 3:05PM CST
Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, announced today that co-founder and Chief Executive Officer, Ryan Ashton, will speak at the 28th Annual ROTH Conference on March 14 at 5PM PDT. Mr. Ashton and Jeff Rona, Great Basin's Chief Financial Officer, will also be available for one-on-one and group meetings with conference participants on March 14 and 15. To schedule a meeting, please contact oneononerequests@roth.com. More information can be found on the ROTH Capital Partners website at www.roth.com
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
Great Basin prices equity offering; shares down 19%
Seeking Alpha - at Seeking Alpha - Fri Feb 19, 8:58AM CST
GBSN: 0.20 (-0.08)
Great Basin Scientific Prices $6.3 Million Public Offering of Units
Business Wire - Fri Feb 19, 8:29AM CST
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, today announced it has priced a public offering of 39.2 million units at a public offering price of $0.16 per unit. The Company expects that the gross proceeds of the offering of the units will be approximately $6.3 million. Each unit will consist of one share of common stock and 1.5 Series E warrants. Each whole Series E warrant will entitle the holder to acquire one share of common stock, subject to adjustment, at an exercise price of $0.25 per share for a period of five years following the date they first become exercisable. The Series E warrants will not be exercisable until at least one year from the date of issuance and exercise of the Series E warrants is subject to certain stockholder approval requirements.
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
CORRECTING and REPLACING Great Basin Announces 201 Customers to End January 2016
Business Wire - Wed Feb 03, 12:30PM CST
Please replace the release due to changes in the fourth paragraph. The original release stated that Great Basin's Staph ID/R Blood Culture panel is a direct from whole blood multiplex panel. The panel is not direct from whole blood.
GBSN: 0.20 (-0.08)
Great Basin Announces 201 Customers to End January 2016
Business Wire - Wed Feb 03, 7:00AM CST
Great Basin Scientific, Inc. (NASDAQ:GBSN) announced today that its customer base grew to 201 sites by the end of January, up from 186 at the end of December 2015, continuing the Company's steady overall growth for its sample-to-result molecular diagnostics platform.
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
Identifying Opportunity in Market Momentum -- New Research on Great Basin Scientific, Aegean Marine Petroleum Network, Crawford & Co, and Kelso Technologies
ACCESSWIRE - Fri Jan 29, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / January 29, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Great Basin Scientific Inc. (NASDAQ: GBSN), Aegean Marine Petroleum Network Inc. (NYSE: ANW), Crawford & Co. (NYSE: CRD.
and Kelso Technologies Inc. (NYSEMKT: KIQ). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis. ANW: 7.50 (+0.27), GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28), CRD.B: 5.78 (-0.04), KIQ: 0.85 (-0.01)
Great Basin's Sandra Nielsen Recognized with Utah Business Annual Sales & Marketer of the Year (SAMY) Award
Business Wire - Tue Jan 26, 7:00AM CST
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, today announced that Utah Business magazine has honored Sandra Nielsen, Vice President, Sales, Marketing & HR with a 2016 SAMY award. The Utah Business SAMY awards aim to recognize Utah's top sales and marketing professionals who have had a measurable impact on their company's bottom line. Ms. Nielsen will accept her award later today during the SAMY Honoree Award Luncheon held at the Grand America Hotel in Salt Lake City.
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
Great Basin Scientific Inc. (NASDAQ: GBSN) Toxic Financing Eliminated from Great Basin's Balance Sheet
ACCESSWIRE - Tue Jan 26, 6:50AM CST
WEST VALLEY, UT / ACCESSWIRE / January 26, 2016 / Great Basin Scientific Inc. (NASDAQ: GBSN) a molecular diagnostics company, announced recently that it has converted all outstanding Series C Warrants into shares of its common stock and therefore now has 75.5 million shares of common stock issued and outstanding, and has no remaining unconverted Series C Warrants. On January 21, 2016, Great Basin converted the remaining 1,221,587 Series C Warrants. It settled 1,416 warrants with cash and settled the remainder by issuing 13.7 million shares of Great Basin common stock. The Company did not issue any of the Pre-funded Rights to acquire its common stock. This toxic financing has been eliminated from GBSN's balance sheet; a step for the better in the eyes of shareholders.
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
Great Basin Announces Conversion of Remaining Series C Warrants
Business Wire - Thu Jan 21, 7:00PM CST
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today that as of 5 p.m. the Company has converted all outstanding Series C Warrants into shares of its common stock and therefore now has 75.5 million shares of common stock issued and outstanding, and has no remaining unconverted Series C Warrants.
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
Great Basin Announces Pricing of Final Series C Warrant Conversions
Business Wire - Wed Jan 20, 9:16PM CST
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, today announced the Company will have sufficient authorized, unreserved and unissued shares of common stock to convert all remaining Series C warrants to shares of its common stock. Therefore, effective 5 p.m. New York City time on Thursday, January 21, 2016, each unexercised Series C warrant will automatically convert into 11.18 shares of Great Basin common stock or to a pre-funded right to acquire 11.18 of shares of Great Basin common stock or a combination thereof. Upon conversion of the remaining Series C Warrants, Great Basin will have approximately 75.5 million shares of common stock outstanding (including pre-funded rights which are convertible into shares of common stock).
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
4 Small Cap NASDAQ/NYSE Stocks That Are Trading with Heavy Volume Today
ACCESSWIRE - Tue Jan 19, 11:52AM CST
NEW YORK, NY / ACCESSWIRE / January 19, 2016 / The Stock Expert is issuing a report on four stocks to watch. CMRX, AEZS, TMST and GBSN have been attracting the attention of major investors today. Continue reading to find out why.
GBSN: 0.20 (-0.08), TMST: 9.04 (+0.73), CMRX: 4.86 (+0.10), AEZS: 3.40 (-0.03)
Great Basin Announces Update of Series C Warrant Conversions
Business Wire - Tue Jan 19, 7:00AM CST
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, today announced that it has approximately 60MM authorized, unreserved and unissued shares remaining and approximately 4.3MM remaining Series C warrants (including Series C Warrants acquirable upon exercise of outstanding options), which, if converted at Friday's closing bid price of $0.15 would require the Company to issue approximately 64MM shares of common stock and would result in an "Authorized Share Failure" as defined under the Series C warrant agreement.
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
Great Basin Announces 186 Customers to End 2015
Business Wire - Tue Jan 05, 7:00AM CST
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, today announced it added 46 new customers in the fourth quarter of 2015. As of December 31st, the company had secured 186 U.S. customers, compared to 84 customers reported at the end of December 2014, representing an increase of 121 percent year over year. Further, Great Basin's Group B Streptococcus (GBS) test--which was commercially launched on June 1, 2015--has now been adopted by or is scheduled to be evaluated by 80 sites, which represents 43 percent of the Company's customer base.
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
4 Small Cap Stocks For Your Portfolio In 2016
ACCESSWIRE - Thu Dec 31, 8:45AM CST
NEW YORK, NY / ACCESSWIRE / December 31, 2015 / UltimateStockAlerts.com is a NASDAQ & NYSE Only Stock Alert Service focused on day trading, swing trading and long-term investing. Our newsletter subscribers have witnessed upside gains in excess of 600% with realized gains of 292% in 2015 from 31 alerts. Receive free trade alerts via email or text message (SMS) on your phone by texting message ULTIMATE to number 555-888. Today we are taking a look at four companies which we believe could provide investors with significant upside.
GBSN: 0.20 (-0.08), GBSNU: 16.22 (-0.28)
